{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:20:13Z","timestamp":1790850013326,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015746","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000}}],"reference-count":155,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015746.pub2","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T06:44:24Z","timestamp":1746513864000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Typhoid conjugate vaccines for preventing typhoid fever (enteric fever)"],"prefix":"10.1002","volume":"2025","author":[{"given":"Natasha R","family":"Gloeck","sequence":"additional","affiliation":[{"name":"Health Systems Research Unit; South African Medical Research Council; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy D","family":"Leong","sequence":"additional","affiliation":[{"name":"Health Systems Research Unit; South African Medical Research Council; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashudu","family":"Mthethwa","sequence":"additional","affiliation":[{"name":"Health Systems Research Unit; South African Medical Research Council; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinwe Juliana","family":"Iwu-Jaja","sequence":"additional","affiliation":[{"name":"Cochrane South Africa; South African Medical Research Council; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick DMC","family":"Katoto","sequence":"additional","affiliation":[{"name":"Office of the President and CEO; South African Medical Research Council; Cape Town South Africa"},{"name":"Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences; Stellenbosch University; Cape Town South Africa"},{"name":"Centre for Tropical Diseases and Global Health, Department of Medicine; Catholic University of Bukavu; Bukavu DRC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S","family":"Wiysonge","sequence":"additional","affiliation":[{"name":"Cochrane South Africa; South African Medical Research Council; Cape Town South Africa"},{"name":"Vaccine-Preventable Diseases Programme; WHO Regional Office for Africa; Brazzaville Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Kredo","sequence":"additional","affiliation":[{"name":"Health Systems Research Unit; South African Medical Research Council; Cape Town South Africa"},{"name":"Division of Clinical Pharmacology, Department of Medicine and Division of Epidemiology and Biostatistics, Department of Global Health; Faculty of Medicine and Health Sciences, Stellenbosch University; Cape Town South Africa"},{"name":"School of Family Medicine and Public Health; University of Cape Town; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD015746.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide\u2013tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"Stanaway","year":"2017","journal-title":"Lancet Infectious Disease"},{"issue":"45","key":"10.1002\/14651858.CD015746.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1016\/j.vaccine.2021.07.073","article-title":"Persisting antibody responses to Vi polysaccharide\u2013tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7\u202fyears following primary vaccination of children < 2\u202fyears of age with, or without, a booster vaccination","volume":"39","author":"Vadrevu","year":"2021","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0004|cit4","first-page":"153","article-title":"Typhoid vaccines: WHO position paper, March 2018 - recommendations","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Weekly Epidemiological Record"},{"issue":"10440","key":"10.1002\/14651858.CD015746.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0006|cit6","unstructured":"World Health Organization Background paper to SAGE on typhoid vaccine policy recommendations. WHO position papers on typhoid. Version date: 24 September 2017 Available from cdn.who.int\/media\/docs\/default-source\/immunization\/position_paper_documents\/typhoid\/1-typhoid-sage-background-paper-final-v3b.pdf?sfvrsn=ddf418c3_2"},{"issue":"8","key":"10.1002\/14651858.CD015746.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.302.8.914","article-title":"JAMA patient page. Typhoid fever","volume":"302","author":"Chang","year":"2009","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015746.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1093\/cid\/ciaa504","article-title":"Review on the recent advances on typhoid vaccine development and challenges ahead","volume":"71","author":"Syed","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"n437","DOI":"10.1136\/bmj.n437","article-title":"Enteric fever","volume":"372","author":"Basnyat","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0010|cit10","unstructured":"Andrews JR Harris JB Ryan ET Typhoid fever, paratyphoid fever, and typhoidal fevers Bennet JR Dolin R Blaser MJ Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases Philadelphia (PA) Elsevier Health Sciences"},{"issue":"2","key":"10.1002\/14651858.CD015746.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"020407","DOI":"10.7189\/jogh.05.020407","article-title":"Systematic review of the global epidemiology, clinical and laboratory profile of enteric fever","volume":"5","author":"Azmatullah","year":"2015","journal-title":"Journal of Global Health"},{"issue":"22","key":"10.1002\/14651858.CD015746.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMra020201","article-title":"Typhoid fever","volume":"347","author":"Parry","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD015746.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"S435","DOI":"10.1093\/cid\/ciz477","article-title":"Occurrence of typhoid fever complications and their relation to duration of illness preceding hospitalization: a systematic literature review and meta-analysis","volume":"69","author":"Cruz Espinoza","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"9973","key":"10.1002\/14651858.CD015746.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/s0140-6736(13)62708-7","article-title":"Typhoid fever","volume":"385","author":"Wain","year":"2016","journal-title":"Lancet"},{"issue":"S3","key":"10.1002\/14651858.CD015746.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"C21","DOI":"10.1016\/j.vaccine.2015.03.102","article-title":"Antimicrobial resistance and management of invasive Salmonella disease","volume":"33","author":"Kariuki","year":"2015","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD015746.pub2-BIB0016|cit16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010452.pub2","article-title":"Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins","author":"Kuehn","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0017|cit17","unstructured":"World Health Organization WASH and health working together: a \u2018how-to\u2019 guide for neglected tropical disease programmes, second edition. 2023 Available from who.int\/publications\/i\/item\/9789240068032"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015746.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the typhoid conjugate vaccine pipeline: current status and future plans","volume":"68","author":"Sahastrabuddhe","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0019|cit19","unstructured":"World Health Organization Immunization, vaccines and biologicials: WHO recommendations for routine immunization - summary tables Available from https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/policies\/who-recommendations-for-routine-immunization---summary-tables"},{"issue":"1","key":"10.1002\/14651858.CD015746.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1073\/pnas.1819612116","article-title":"On the mechanisms of conjugate vaccines","volume":"116","author":"Rappuoli","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"26","key":"10.1002\/14651858.CD015746.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.vaccine.2016.03.106","article-title":"Status of paratyphoid fever vaccine research and development","volume":"34","author":"Martin","year":"2016","journal-title":"Vaccine"},{"issue":"10436","key":"10.1002\/14651858.CD015746.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/S0140-6736(24)00461-6","article-title":"Bivalent conjugate vaccines for typhoid and paratyphoid fever","volume":"403","author":"Raqib","year":"2024","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijid.2020.10.103","article-title":"Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso","volume":"102","author":"Sirima","year":"2021","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0024|cit24","unstructured":"Hughes M Appiah G Watkins LF Travel-associated infections and diseases. Typhoid & paratyphoid fever. In: Nemhauser J, Halsey E, LaRocque R, Alvarado-Ramy F, Angelo K, Ericsson C, et al (editors). CDC Yellow Book 2024 Available from: https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2024\/infections-diseases\/typhoid-and-paratyphoid-fever"},{"issue":"2","key":"10.1002\/14651858.CD015746.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"e00084","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccines","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clinical Microbiology Reviews"},{"issue":"7","key":"10.1002\/14651858.CD015746.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.15585\/mmwr.mm7207a2","article-title":"Typhoid fever surveillance, incidence estimates, and progress toward typhoid conjugate vaccine introduction \u2014 worldwide, 2018\u20132022","volume":"72","author":"Hancuh","year":"2023","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"E535","DOI":"10.1016\/s2214-109x(24)00055-x","article-title":"Typhoid conjugate vaccines: a step towards typhoid control","volume":"12","author":"Shayka","year":"2024","journal-title":"Lancet Global Health"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1473-3099(21)00560-0","article-title":"Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines","volume":"22","author":"Gibani","year":"2022","journal-title":"Lancet Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD015746.pub2-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001261.pub4","article-title":"Vaccines for preventing typhoid fever","author":"Milligan","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0030|cit30","unstructured":"Higgins JPT Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews Cochrane: London, Version August 2023"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0032|cit32","unstructured":"Covidence Veritas Health Innovation 2023"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0034|cit34","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0036|cit36","unstructured":"Higgins JPT Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook"},{"issue":"10301","key":"10.1002\/14651858.CD015746.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015746.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/cid\/ciac289","article-title":"Prevention of typhoid by Vi conjugate vaccine and achievable improvements in household water, sanitation, and hygiene: evidence from a cluster-randomized trial in Dhaka, Bangladesh","volume":"75","author":"Tadesse","year":"2022","journal-title":"Clinical Infectious Disease"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0039|cit39","unstructured":"Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among Bangladeshi children \u2013 a Phase IV trial isrctn.com\/ISRCTN11643110"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015746.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1093\/cid\/ciy1107","article-title":"Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among Bangladeshi children: a protocol for a phase IIIb trial","volume":"68","author":"Theiss-Nyland","year":"2019","journal-title":"Clinical Infectious Disease"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Theiss-Nyland K Shakya M Colin-Jones R Voysey M Smith N Karkey A Erratum: assessing the Impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infections among Nepalese children: a protocol for a phase III, randomized control trial Clinical Infectious Diseases 2021 73 10 1950 10.1093\/cid\/ciab802 34698813","DOI":"10.1093\/cid\/ciab802"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0042|cit42","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0043|cit43","unstructured":"Higgins JPT Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0044|cit44","unstructured":"Review Manager (RevMan) The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0047|cit47","unstructured":"Deeks JJ Higgins JPT Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023) Available from training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD015746.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0049|cit49","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/21645515.2015.1117715","article-title":"Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph TM) in Indian children: school based cluster randomized study","volume":"12","author":"Mitra","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0051|cit51","unstructured":"Incidence of typhoid fever as observed over 1 year in children aged 6 months-12 years after receiving conjugated typhoid vaccine (Peda Typh TM) versus a similar non-vaccinated group in the same locality in Kolkata ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=4714&EncHid=&userName=Vi-TT"},{"issue":"2","key":"10.1002\/14651858.CD015746.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0053|cit53","unstructured":"Safety and immunogenicity of Vi-CRM197 vaccine against S. typhi in children, older infants and infants classic.clinicaltrials.gov\/ct2\/show\/NCT01437267"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0054|cit54","unstructured":"Safety and immunogenicity of Vi-CRM197 vaccine against S. typhi in adults, children, older infants and infants clinicaltrials.gov\/show\/NCT01229176"},{"issue":"26","key":"10.1002\/14651858.CD015746.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: phase I trial in healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0056|cit56","unstructured":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine clinicaltrials.gov\/show\/NCT02645032"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"100540","DOI":"10.1016\/j.eclinm.2020.100540","article-title":"Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: phase II, randomized, dose-scheduling, observer-blind study","volume":"27","author":"Capeding","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1002\/14651858.CD015746.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41541-022-00434-8","article-title":"Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose","volume":"7","author":"Capeding","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"28","key":"10.1002\/14651858.CD015746.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1016\/j.vaccine.2019.09.074","article-title":"Immunogenicity, safety and reactogenicity of a phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: a preliminary report","volume":"38","author":"Capeding","year":"2020","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0060|cit60","unstructured":"Safety, reactogenicity and immunogenicity of Vi-DT clinicaltrials.gov\/show\/NCT03527355"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"100484","DOI":"10.1016\/j.lanwpc.2022.100484","article-title":"A phase 3, multicenter, randomized, controlled trial to evaluate immune equivalence and safety of multidose and single-dose formulations of Vi-DT typhoid conjugate vaccine in healthy Filipino individuals 6 months to 45 years of age","volume":"24","author":"Carlos","year":"2022","journal-title":"Lancet Regional Health. Western Pacific"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0062|cit62","unstructured":"Immune equivalence between multi-dose and single dose formulation of Vi-DT and their overall safety (phase III) clinicaltrials.gov\/show\/NCT04204096"},{"issue":"19","key":"10.1002\/14651858.CD015746.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.vaccine.2021.03.089","article-title":"An open-label, comparative, single dose, clinical phase I study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults","volume":"39","author":"Choi","year":"2021","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0064|cit64","unstructured":"Safety and tolerability of typhoid conjugate vaccine (EuTCV) in healthy adults clinicaltrials.gov\/study\/NCT03956524"},{"issue":"10","key":"10.1002\/14651858.CD015746.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.vaccine.2022.12.007","article-title":"A phase II\/III, multicenter, observer-blinded, randomized, non-inferiority and safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV R in healthy 6 months-45 years aged participants","volume":"41","author":"Ok Baik","year":"2023","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0066|cit66","unstructured":"Non-inferiority and safety study of EuTCV compared to Typbar-TCV in healthy 6 months-45 years aged participants clinicaltrials.gov\/study\/NCT04830371"},{"issue":"7","key":"10.1002\/14651858.CD015746.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s13312-020-1890-y","article-title":"Immunogenicity and safety of typhoid conjugate vaccine in healthy Indian subjects: a randomized, active-controlled, comparative clinical trial","volume":"57","author":"Kundu","year":"2020","journal-title":"Indian Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD015746.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0069|cit69","unstructured":"A study to evaluate the immunogenicity and safety of BBILs typhoid Vi capsular polysaccharide-tetanus toxoid protein conjugate vaccine vs reference vaccine in healthy subjects ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=MzI0MQ==&Enc=&userName=CTRI\/2011\/08\/001957"},{"issue":"5","key":"10.1002\/14651858.CD015746.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"2043103","DOI":"10.1080\/21645515.2022.2043103","article-title":"A multicenter, single-blind, randomized, phase-2\/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator","volume":"18","author":"Thuluva","year":"2022","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0071|cit71","unstructured":"A clinical study to assess the safety and immune response with typhoid conjugate vaccine of BE when compared with a licensed typhoid conjugate vaccine ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=Mjk0MTY=&Enc=&userName=CTRI\/2018\/11\/016419"},{"issue":"1","key":"10.1002\/14651858.CD015746.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40794-023-00210-z","article-title":"A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity","volume":"10","author":"Koesnoe","year":"2024","journal-title":"Tropical Disease, Travel Medicine and Vaccines"},{"issue":"1","key":"10.1002\/14651858.CD015746.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12887-020-02375-4","article-title":"A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report","volume":"20","author":"Medise","year":"2020","journal-title":"BMC Pediatrics"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijid.2020.01.045","article-title":"One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: safety and immunogenicity of Vi-DT typhoid conjugate vaccine","volume":"93","author":"Medise","year":"2020","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0075|cit75","unstructured":"Safety and immunogenicity of Vi-DT typhoid conjugate vaccine in Indonesian adults, adolescents, children and infants clinicaltrials.gov\/show\/NCT03460405"},{"issue":"2","key":"10.1002\/14651858.CD015746.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"e0211784","DOI":"10.1371\/journal.pone.0211784","article-title":"Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine","volume":"14","author":"Medise","year":"2019","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0077|cit77","unstructured":"Safety and immunogenicity of Vi-DT typhoid conjugate vaccine (Bio Farma) in adults and children (Phase I) clinicaltrials.gov\/show\/NCT03109600"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1473-3099(21)00455-2","article-title":"Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial","volume":"22","author":"Kumar Rai","year":"2022","journal-title":"Lancet Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD015746.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"2203634","DOI":"10.1080\/21645515.2023.2203634","article-title":"A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal","volume":"19","author":"Chaudhary","year":"2023","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0080|cit80","unstructured":"Immune non-inferiority and safety of a Vi-DT typhoid conjugate vaccine https:\/\/clinicaltrials.gov\/show\/NCT03933098"},{"issue":"1","key":"10.1002\/14651858.CD015746.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"2301631","DOI":"10.1080\/21645515.2023.2301631","article-title":"Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): findings from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers","volume":"20","author":"Tamrakar","year":"2024","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"11","key":"10.1002\/14651858.CD015746.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"e1561","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Global Health"},{"issue":"23","key":"10.1002\/14651858.CD015746.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0084|cit84","unstructured":"Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among Nepalese children \u2013 a phase III trial isrctn.com\/ISRCTN43385161"},{"issue":"17","key":"10.1002\/14651858.CD015746.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD015746.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJM200310023491423","article-title":"Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children","volume":"349","author":"Mai","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"10425","key":"10.1002\/14651858.CD015746.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s0140-6736(23)02031-7","article-title":"Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children","volume":"403","author":"Patel","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD015746.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in Malawian children","volume":"385","author":"Patel","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0089|cit89","unstructured":"Clinical efficacy of typhoid conjugate vaccine (Vi-TCV) among children age 9 months through 12 years in Blantyre, Malawi clinicaltrials.gov\/show\/NCT03299426"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015746.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1093\/cid\/ciy1103","article-title":"Typhoid Vaccine Acceleration Consortium Malawi: a phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi","volume":"68","author":"Meiring","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD015746.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"e1326","DOI":"10.1016\/S2214-109X(22)00275-3","article-title":"Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial","volume":"10","author":"Nampota-Nkomba","year":"2022","journal-title":"Lancet Global Health"},{"issue":"12","key":"10.1002\/14651858.CD015746.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1016\/S2666-5247(21)00310-4","article-title":"A trial of a typhoid conjugate vaccine in children in Malawi","volume":"2","author":"Venkatesan","year":"2021","journal-title":"Lancet Microbe"},{"issue":"9","key":"10.1002\/14651858.CD015746.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"e25398","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"Damme","year":"2011","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0094|cit94","unstructured":"Safety and immunogenicity of three formulations of Vi-CRM197 vaccine against S. Typhi in adults (18-40 years old) clinicaltrials.gov\/show\/NCT01193907"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0095|cit95","unstructured":"Safety and immunogenicity of Vi-CRM197 vaccine against S. typhi in adults (18-40 years old) clinicaltrials.gov\/show\/NCT01123941"},{"issue":"10111","key":"10.1002\/14651858.CD015746.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0097|cit97","unstructured":"Vaccines Against Salmonella Typhi (VAST) clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2014-002978-36-GB"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0098|cit98","unstructured":"Vaccines against Salmonella Typhi (VAST) clinicaltrials.gov\/show\/NCT02324751"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0099|cit99","unstructured":"TypbarTCV-Typhoid vaccine Phase-IV clinical trial Compare to Sanofi Pasteur\u2019s Typhim Vi\u00ae vaccine ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=MTI2MTg=&Enc=&userName=CTRI\/2016\/01\/006476"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0100|cit100","unstructured":"Clinical study to assess the immune response and safety of typhoid conjugate vaccine of Cadila Healthcare Limited and compare it to typhoid conjugate vaccine of Bharat Biotech International Limited in healthy human subjects ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=MTUxNzE=&Enc=&userName=CTRI\/2016\/05\/006975"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0101|cit101","unstructured":"A clinical study to vaccinate healthy adults with a single human dose of a licensed typhoid conjugate vaccine and collection of immune sera for development of testing standards for anti-typhoid antibody estimation ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=MjA2ODk=&Enc=&userName=CTRI\/2018\/01\/011500"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0102|cit102","unstructured":"A clinical research study to assess the immune response and safety of two typhoid vaccines in healthy adult subjects of 45 to 65 years of age ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=NjA1Mzk=&Enc=&userName=CTRI\/2021\/09\/036577"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0103|cit103","unstructured":"Understanding typhoid disease after vaccination: a single centre, randomised, double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy adult challenge model, using Ty21a vaccine as a positive control clinicaltrialsregister.eu\/ctr-search\/trial\/2011-000381-35\/GB"},{"issue":"2","key":"10.1002\/14651858.CD015746.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"e20201116","DOI":"10.1084\/jem.20201116","article-title":"Vi-specific serological correlates of protection for typhoid fever","volume":"218","author":"Jin","year":"2021","journal-title":"Journal of Experimental Medicine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"101925","DOI":"10.1016\/j.eclinm.2023.101925","article-title":"Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis","volume":"58","author":"Khanam","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"19","key":"10.1002\/14651858.CD015746.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1016\/j.vaccine.2023.04.014","article-title":"Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh","volume":"41","author":"Khanam","year":"2023","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0107|cit107","unstructured":"Persistence and long-term protection of Vi antibodies induced by Vi-DT conjugate vaccines in Indonesian clinicaltrials.gov\/study\/NCT04741828"},{"issue":"1","key":"10.1002\/14651858.CD015746.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/cid\/cix1145","article-title":"Seroefficacy of Vi polysaccharide-tetanus toxoid typhoid conjugate vaccine (Typbar TCV)","volume":"67","author":"Voysey","year":"2018","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0109|cit109","unstructured":"Typhoid Vi vaccine effectiveness in Hechi, Guangxi, China clinicaltrials.gov\/show\/NCT00131833"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0110|cit110","unstructured":"Immunogenicity, safety and tolerability of the typhoid fever vaccine candidate M01ZH09 in healthy adults clinicaltrials.gov\/show\/NCT00679172"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0111|cit111","unstructured":"Co-administration study of OCV, TCV and MR clinicaltrials.gov\/study\/NCT05771779"},{"issue":"40","key":"10.1002\/14651858.CD015746.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"5828","DOI":"10.1016\/j.vaccine.2022.08.034","article-title":"Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants","volume":"40","author":"Saluja","year":"2022","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijid.2020.10.103","article-title":"Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso","volume":"102","author":"Sirima","year":"2021","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0114|cit114","unstructured":"Typhoid conjugate vaccine trial among children younger than 2 years in Ouagadougou, Burkina Faso clinicaltrials.gov\/show\/NCT03614533"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ijid.2021.05.061","article-title":"Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial","volume":"108","author":"Sirima","year":"2021","journal-title":"International Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD015746.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1128\/CVI.00058-12","article-title":"Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans","volume":"19","author":"Wahid","year":"2012","journal-title":"Clinical and Vaccine Immunology"},{"issue":"3","key":"10.1002\/14651858.CD015746.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/vaccines9030281","article-title":"Evaluation of typhoid conjugate vaccine effectiveness in Ghana (Tyvegha) using a cluster-randomized controlled phase iv trial: trial design and population baseline characteristics","volume":"9","author":"Haselbeck","year":"2021","journal-title":"Vaccines"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0118|cit118","unstructured":"Effectiveness of a typhoid conjugate vaccine in DRC (TyVECO) clinicaltrials.gov\/study\/NCT05119426"},{"issue":"9","key":"10.1002\/14651858.CD015746.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1473-3099(19)30425-6","article-title":"Typhoid Vi-conjugate vaccine for outbreak control in Zimbabwe","volume":"19","author":"Olaru","year":"2019","journal-title":"Lancet Infectious Diseases"},{"issue":"22","key":"10.1002\/14651858.CD015746.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMc091690","article-title":"A cluster-randomized effectiveness trial of Vi typhoid vaccine in India","volume":"361","author":"Schwartz","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0121|cit121","unstructured":"A Phase 2, open-label, single-center, extension study to evaluate the response induced by vaccination with Vi-CRM197 1 year after initial vaccination with either Vi-CRM197 or Typherix, which was administered in adult subjects in H01_04TP study www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001448-31\/BE"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0122|cit122","unstructured":"A phase 2, randomized, observer\u2013blind, controlled, single center study to evaluate the safety and immunogenicity of three formulations of the NVGH glycoconjugate vaccine against S. typhi in adult subjects 18 to 40 years of age clinicaltrialsregister.eu\/ctr-search\/trial\/2010-021874-12\/BE"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0123|cit123","unstructured":"A phase II, single-centre, randomised, single-blind, study to evaluate Vi-CRM197 against historical unvaccinated controls in a healthy adult challenge model, with a Vi-PS vaccine control arm clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2011-003653-26-GB"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0124|cit124","first-page":"383","article-title":"Three year efficacy results from an individually randomized controlled double-blind trial of a typhoid conjugate vaccine in Malawi","volume":"108","author":"Patel","year":"2023","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"109","DOI":"10.13181\/mji.v7iSupp1.1052","article-title":"Phase II trials of conjugates of S.typhi Vi and of S.paratyphi A O-specific polysaccharide (O-SP) conjugates in Dong Thap province, Vietnam","volume":"7","author":"Szu","year":"1998","journal-title":"Medical Journal of Indonesia"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD015746.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4269\/ajtmh.abstract2018","article-title":"A randomized, observer-blinded, phase I study to assess the safety and immunogenicity of VI-DT conjugate vaccine compared to VI-polysaccharide (typhim VI, sanofi pasteur) typhoid vaccine in healthy Filipino adults and children","volume":"99","author":"Tesema","year":"2018","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0127|cit127","unstructured":"To determine long term persistence of immune response of Typbar TCV ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=Mjc1ODc=&Enc=&userName=CTRI\/2019\/04\/018634"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0128|cit128","unstructured":"Assessing the impact of a typhoid conjugate vaccine introduced in an urban community ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=NjI1NDg=&Enc=&userName=CTRI\/2022\/03\/041314"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0129|cit129","unstructured":"A phase I clinical study to assess the safety and tolerability of SII typhoid conjugate vaccine (bivalent) in healthy adults ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=NzA5Nzc=&Enc=&userName=CTRI\/2022\/06\/043608"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0130|cit130","unstructured":"Immunogenicity and safety of Vi-DT (diphtheria toxoid) typhoid conjugate vaccine (phase III) clinicaltrials.gov\/show\/NCT04051268"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0131|cit131","unstructured":"Evaluation of typhoid conjugate vaccine effectiveness in Ghana (TyVEGHA) clinicaltrials.gov\/study\/NCT04852185"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0132|cit132","unstructured":"Non-inferiority trial of locally manufactured typhoid conjugate vaccine 'Typhocon' in Bangladesh clinicaltrials.gov\/study\/NCT05475379"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0133|cit133","unstructured":"A study to evaluate safety, reactogenicity, and immune response of GVGH iNTS-TCV vaccine against invasive nontyphoidal salmonella and typhoid fever clinicaltrials.gov\/study\/NCT05480800"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0134|cit134","unstructured":"Vellore typhoid vaccine impact trial (VEVACT) clinicaltrials.gov\/study\/NCT05500482"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0135|cit135","unstructured":"Safety and immunogenicity of a novel conjugate vaccine against Salmonella Typhi and Salmonella Paratyphi A in healthy adults clinicaltrials.gov\/study\/NCT05613205"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0136|cit136","unstructured":"Trivalent Salmonella conjugate vaccine (TSCV) clinicaltrials.gov\/show\/NCT05784701"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0137|cit137","unstructured":"A cluster-randomised controlled Phase IV trial (cRCT) assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection in Asante Akim, Ghana (TyVEGHA) pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=14529"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0138|cit138","unstructured":"Phase 3 EuTCV Trial in Africa pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=16067"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0139|cit139","unstructured":"Metreau E Young KE Eapen SG World Bank country classifications by income level for 2024-2025 Available from blogs.worldbank.org\/en\/opendata\/world-bank-country-classifications-by-income-level-for-2024-2025"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0140|cit140","unstructured":"Peryer G Golder S Junqueira D Vohra S Loke YK Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023) Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/RRTM.S282461","article-title":"The burden of typhoid fever in sub-Saharan Africa: a perspective","volume":"13","author":"Kim","year":"2022","journal-title":"Research and Reports in Tropical Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1016\/S2214-109X(23)00606-X","article-title":"Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis","volume":"12","author":"Batool","year":"2024","journal-title":"Lancet Global Health"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0143|cit143","unstructured":"World Health Organization Typhoid. Version 30 March 2023 Available from who.int\/news-room\/fact-sheets\/detail\/typhoid"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0144|cit144","unstructured":"World Health Organization Burden of disease attributable to unsafe drinking-water, sanitation and hygiene, 2019 update Available from iris.who.int\/bitstream\/handle\/10665\/370026\/9789240075610-eng.pdf?sequence=1"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0145|cit145","unstructured":"Typhoid conjugate vaccine: supply and demand update. December 2022 Available from unicef.org\/supply\/media\/15236\/file\/Typhoid-Conjugate-Vaccine-Supply-and-Demand-Update-December-2022.pdf"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3389\/fmicb.2020.01526","article-title":"Impact of vaccines: health, economic and social perspectives","volume":"11","author":"Rodrigues","year":"2020","journal-title":"Frontiers in Microbiology"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0147|cit147","unstructured":"World Health Organization WHO - prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control): prequalified vaccines Available from extranet.who.int\/pqweb\/vaccines\/prequalified-vaccines"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/21645515.2015.1117715","article-title":"Efficacy and safety of vi-tetanus toxoid conjugated vaccine (PedaTyph\u2122) in Indian children: school based cluster randomized study","volume":"12","author":"Mitra","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0149|cit149","unstructured":"World Health Organization TYPHIBEV: vaccine public summary assessment report (VPSAR) Available from extranet.who.int\/prequal\/vaccines\/p\/typhibevr-0"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"100540","DOI":"10.1016\/j.eclinm.2020.100540","article-title":"Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: phase II, randomized, dose-scheduling, observer-blind study","volume":"27","author":"Capeding","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41541-022-00434-8","article-title":"Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose","volume":"7","author":"Capeding","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"4","key":"10.1002\/14651858.CD015746.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/s1473-3099(21)00455-2","article-title":"Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial","volume":"22","author":"Kumar Rai","year":"2022","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015746.pub2-BIB0153|cit153","unstructured":"World Health Organization WHO prequalification of medical products: SKYTyphoid Multi Inj Available from extranet.who.int\/prequal\/vaccines\/p\/skytyphoid-multi-inj"},{"issue":"17","key":"10.1002\/14651858.CD015746.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015746.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1586\/14760584.2013.845529","article-title":"Development of Vi conjugate - a new generation of typhoid vaccine","volume":"12","author":"Szu","year":"2013","journal-title":"Expert Review of Vaccines"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:18:07Z","timestamp":1776410287000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015746.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":155,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015746.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}